Abstract
Screening cardiovascular disease (CVD) risk is an important part of CVD prevention. The success of screening is dependent on the rigour with which treatments are subsequently prescribed. AIM To establish the extent to which treatment conforms to guidelines. Cross-sectional study of anonymised patient records from 19 general practices in the UK. Data relating to patient characteristics, including CVD risk factors, risk score and prescribed medication were extracted. CVD risk (thus eligibility for cholesterol and blood pressure-lowering treatment) was calculated using the Framingham equation. Guideline adherence was defined with descriptive statistics and comparisons by age, sex and disease were made using χ(2) tests. Of the 34 975 patients (aged 40-74 years) included in this study, 2550 (7%) patients had existing CVD and 12 349 (35%) had a calculable CVD risk or were on treatment. CVD risk was formally assessed in 8390 (24%) patients. Approximately 7929 (64%) patients eligible for primary prevention therapy were being treated appropriately for their CVD risk. Guideline adherence was higher in younger patients (6284 [69%] aged 40-64 years versus 1645 [50%] aged 65-74 years, P<0.001) and in females (4334 [69%] females versus 3595 [59%] males, P<0.001). There was no difference in guideline adherence between patients where CVD risk had been recorded and those where CVD was calculable. Guideline adherence in patients with existing CVD was highest in patients with ischaemic heart disease (866 [ischaemic heart disease], 52%, versus 288 [stroke], 46%, versus 276 [other CVD], 39%; P<0.001). There is scope for improvement in assessment and treatment for prevention of CVD in clinical practice. Increasing the uptake of evidence-based treatments would improve the cost-effectiveness of CVD risk screening programmes.
Highlights
Cardiovascular disease (CVD) is a leading cause of mortality and accounts for more than one-fifth of all deaths worldwide.[1]
There was no difference in guideline adherence between patients where cardiovascular disease (CVD) risk had been recorded and those where CVD was calculable
Increasing the uptake of evidence-based treatments would improve the cost-effectiveness of CVD risk screening programmes
Summary
Cardiovascular disease (CVD) is a leading cause of mortality and accounts for more than one-fifth of all deaths worldwide.[1] Blood pressure, smoking status, and serum cholesterol concentration are the most important modifiable risk factors for CVD, and more deaths are attributable to these than any other major disease risk factors.[2] national and international guidelines on the management of CVD include significant promotion of CVD prevention through pharmacological control of blood pressure and lipid levels plus encouragement of behavioural change and lifestyle modification.[3,4,5,6,7,8,9] Despite these guidelines, previous studies have identified under-treatment of patients for CVD prevention in specific at-risk groups. The success of screening is dependent on the rigour with which treatments are subsequently prescribed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
